Back
Compare AU
Compare MICH vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Magellan Infra Fund (Currency Hedged) - Active ETF (MICH) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
MICH | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 12 | 73 |
Median incremental investment | $1,143.63 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,452.53 | $1,734.78 |
Average age group | > 35 | > 35 |
Key Summary
MICH | CURE | |
|---|---|---|
Strategy | MICH.AX was created on 2016-07-19 by Magellan. The fund's investment portfolio concentrates primarily on theme equity. To achieve attractive risk adjusted returns over the medium to long-term, While reducing the risk of permanent capital loss | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Aena SME SA (6.46 %) Severn Trent PLC (5.77 %) Ferrovial SE (5.40 %) | Avidity Biosciences Inc Ordinary Shares (2.45 %) Revolution Medicines Inc Ordinary Shares (2.36 %) Insmed Inc (2.14 %) |
Top 3 industries | Utilities (46.48 %) Industrials (29.85 %) Other (13.74 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (38.21 %) Spain (15.62 %) United Kingdom of Great Britain and Northern Ireland (14.04 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 1.05 % | 0.45 % |
Key Summary
MICH | CURE | |
|---|---|---|
Issuer | Magellan | Global X |
Tracking index | S&P Global Infrastructure Hedged to USD Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 1.05 % | 0.45 % |
Price | $3.21 | $59.82 |
Size | N/A | $38.099 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.14 % | 5.08 % |
Market | ASX | ASX |
First listed date | 22/07/2016 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
MICH | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 12 | 73 |
Median incremental investment | $1,143.63 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,452.53 | $1,734.78 |
Average age group | > 35 | > 35 |
Pros and Cons
MICH | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
MICH | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |